Alector, Inc. (ALEC)

Alector's stock price has been volatile, with a significant increase from April 2025 to April 2026. A Phase 3 clinical trial failure in October 2025 led to a stock plunge and workforce reductions. The company is now focused on its ABC platform and AL101, with an interim futility analysis expected in the first half of 2026. Analyst ratings are a consensus "Hold", with an average 12-month price target of $4.17. Insider selling has been observed in the past three months.

Alector, Inc. does not typically experience demand seasonality for its products and services. Demand is driven by clinical trial progress, regulatory approvals, and the medical need for effective treatments for neurodegenerative diseases.

Alector, Inc. is a clinical-stage biotechnology company focused on immuno-neurology therapies for neurodegenerative diseases like Alzheimer's and Parkinson's. Their pipeline leverages human genetics, neuroscience, and immunology to remove toxic proteins, replace deficient proteins, and restore immune and nerve cell function. Key product candidates include Nivisnebart (AL101/GSK4527226), AL137, AL050, AL064, ADP062-ABC, ADP065-ABC, and the Alector Brain Carrier (ABC) platform.

Alector, Inc. is headquartered in South San Francisco, California, and is strategically focused on expanding its presence in international markets, particularly in Europe and Asia.

Alector's brand reputation was negatively impacted by the Phase 3 clinical trial failure of latozinemab (AL001) in October 2025. This led to a negative market reaction and workforce reductions. However, the company's strategic pivot and ongoing collaborations demonstrate a commitment to advancing therapies for neurodegenerative diseases.

Alector, Inc. has a significant level of institutional ownership, with 85.83% of the stock held by institutions. Major institutional owners include TCG Crossover Management, LLC, BlackRock, Inc., Vanguard Group Inc, Foresite Capital Management, LLC, Merck & Co., Inc., Acadian Asset Management Llc, 683 Capital Management, LLC, Balyasny Asset Management Llc, D. E. Shaw & Co., Inc., and Fmr Llc. Insiders hold 9.70% of the stock.